Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity Consistency and Safety of Zifivax (ZF2001) in Adults
NCT05091411Phase 3Unknown
- Sponsor
- Zhifei Biological
- Start
- Sep 2021
- Primary completion
- Nov 2021
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ZF2001 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Zhifei Biological. Primary endpoint: Neutralizing Antibody Response (Live Virus). Status: unknown.
02
Drugs
ZF2001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05091411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05091411.